缬沙坦治疗肾移植术后红细胞增多症

Treatment of postrenal transplant erythrocytosis with Diovan

目的 :探讨血管紧张素 受体拮抗剂缬沙坦治疗肾移植后红细胞增多症的效果和安全性。方法 :12例肾移植后红细胞增多症患者接受缬沙坦治疗 6个月 (80 mg/ d) ,服用药物后观察血红细胞比容、血肌酐、血钾、白细胞及血小板计数变化情况。结果 :服用缬沙坦后 1个月 ,过高的红细胞比容明显下降 ,其中部分患者在服用药物 2周后红细胞比容下降至正常水平 ,且红细胞比容降至正常后 ,不因药物的继续应用而进一步下降 ,而是稳定在正常范围内。缬沙坦对患者血肌酐、血钾、白细胞及血小板计数无明显影响。结论 :缬沙坦治疗肾移植后红细胞增多症安全、有效。

Purpose:To investigate the efficacy and safety of angiotensin Ⅱ receptor antagonist Diovan for the treatment of postrenal transplant erythrocytosis. Method:12 patients with postrenal transplant erythrocytosis were treated with Diovan for 6 months(80 mg/d). The hematocrit, serum creatinine, serum potassium, white blood cell and platelet were observed.Results:The hematocrit in some patients returned to normal in two weeks. A significant fall in hematocrit occurred over the first month. The hematocrit had been stabilized and no patient became anemia. White blood cell and platelet counts were unaffected by Diovan.Serum creatinine and serum potassium remained unchanged throughout the treatment period. Conclusion:Angiotensin Ⅱ receptor antagonist Diovan is a safe and effective therapy for postrenal transplant erythrocytosis.